Scientific Sessions 2025  /  Arteries and Veins in Trouble: VTE and PAD  /  Efficacy and Safety of Imatinib Therapy Administered in Patients with Pulmonary Tumor Thrombotic Microangiopathy (PTTM) : A Prospective, Multi-Center Exploratory Clinical Trial
Logo

American Heart Association

  21
  0

Final ID:

Efficacy and Safety of Imatinib Therapy Administered in Patients with Pulmonary Tumor Thrombotic Microangiopathy (PTTM) : A Prospective, Multi-Center Exploratory Clinical Trial

Abstract Body (Do not enter title and authors here): Background: Pulmonary tumor thrombotic microangiopathy (PTTM) is a cancer-associated pulmonary artery embolism-like condition with a poor prognosis that is fatal in a short time due to pulmonary hypertension and respiratory and right heart failure. Although the incidence of cancer is increasing in Japan, the prognosis has been improving due to advances in treatment, so that PTTM would be fatal and has a significant impact on the prognosis of patients with cancer. Several reports have shown that imatinib, a tyrosine kinase inhibitor, is effective in the treatment of PTTM, however, there is no established evidence for efficacy and safety in using imatinib in PTTM therapy. The purpose of this trial is to evaluate the safety and efficacy of imatinib administration in patients complicated with PTTM.
Study Design/Methods: This was a multicenter, open-label, exploratory clinical trial (jRCTs031210263). Inclusion criteria were 20 years of age or older adults with a burden of cancer, right heart catheterization or echocardiography showing pulmonary hypertension (mean pulmonary artery pressure ≧25 mmHg or estimated right ventricular systolic pressure ≧40 mmHg), and progressive hypoxemia. In parallel with this prospective trial, we conducted a multicenter retrospective registry study of PTTM and patients enrolled in this retrospective registry who did not receive imatinib were set as the control group. Intervention: Participants received dose of oral imatinib 200 mg once daily. Primary endpoint: overall survival after imatinib administration. Secondary endpoints: hemodynamics, BNP levels, quality of life, 6-minute walk distance, imatinib blood levels at the second week of treatment, and time to rehospitalization.
Results: In total, 11 PTTM patients were enrolled and treated with imatinib, and over 100 PTTM patients without imatinib administration were registered as historical control.
Conclusion: We report the primary endpoint of this multicenter exploratory clinical trial of the efficacy and safety of imatinib in patients with PTTM.
  • Shimbo, Mai  ( The University of Tokyo , Tokyo , Japan )
  • Sugimura, Koichiro  ( International University of Health and Welfare Narita Hospital , Narita , Japan )
  • Ogo, Takeshi  ( National Cerebral and Cardiovascular Center , Suita , Japan )
  • Taniguchi, Yu  ( Kobe University , Kobe , Japan )
  • Nakamura, Kazufumi  ( OKAYAMA UNIVERSITY , Okayama , Japan )
  • Kashiwabara, Kosuke  ( THE UNIVERSITY OF TOKYO HOSPITAL , Tokyo , Japan )
  • Komuro, Issei  ( The University of Tokyo , Tokyo , Japan )
  • Takeda, Norihiko  ( The University of Tokyo , Tokyo , Japan )
  • Hatano, Masaru  ( The University of Tokyo , Tokyo , Japan )
  • Minatsuki, Shun  ( The University of Tokyo , Tokyo , Japan )
  • Ishii, Satoshi  ( The University of Tokyo , Tokyo , Japan )
  • Hirose, Miku  ( Nagoya University Hospital , Aichi, Nagoya , Japan )
  • Adachi, Shiro  ( Nagoya University Hospital , Aichi, Nagoya , Japan )
  • Hosokawa, Kazuya  ( Kyushu university , Fukuoka , Japan )
  • Abe, Kohtaro  ( KYUSHU UNIVERSITY , Fukuoka , Japan )
  • Koyama, Masayuki  ( Sapporo Medical University , Sapporo , Japan )
  • Yaoita, Nobuhiro  ( Tohoku University Hospital , Sendai , Japan )
    • Author Disclosures:
    Mai Shimbo: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):a department endowed by HIMEDIC Inc. and Siemens Healthcare K.K:Past (completed) | Koichiro Sugimura: No Answer | Takeshi Ogo: DO NOT have relevant financial relationships | Yu TANIGUCHI: DO NOT have relevant financial relationships | Kazufumi Nakamura: DO NOT have relevant financial relationships | Kosuke Kashiwabara: No Answer | Issei Komuro: No Answer | Norihiko Takeda: DO NOT have relevant financial relationships | Masaru Hatano: No Answer | Shun Minatsuki: No Answer | Satoshi ISHII: No Answer | Miku Hirose: No Answer | Shiro Adachi: No Answer | Kazuya Hosokawa: DO NOT have relevant financial relationships | Kohtaro Abe: DO NOT have relevant financial relationships | Masayuki Koyama: DO NOT have relevant financial relationships | Nobuhiro Yaoita: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Arteries and Veins in Trouble: VTE and PAD

Saturday, 11/08/2025 , 09:45AM - 11:00AM

Featured Science

More abstracts on this topic:
Cardiotoxicity of Anthracycline and Pembrolizumab Compared to Anthracycline Alone in Management of Triple-Negative Breast Cancer: A Retrospective Cohort Study

Holley Nolan, Kurian Sobha, Patel Brijesh, Monroe Gary, Gallagher Micheal, Ahmad Syed, Inderbitzin-fischer Sonya, Hartzell Michelle, Tella Pranathi, Batool Izza, Hill Jordan

A Meta-Analysis of Randomized Controlled Trials: Aldosterone Synthase Inhibitors as a Therapeutic Strategy for Hypertension

Marzano Luigi, Merlo Matteo, Pizzolo Francesca, Friso Simonetta

More abstracts from these authors:
Activation of prostaglandin E receptor 4 attenuates pulmonary vascular remodeling and pulmonary hypertension in monocrotaline-exposed rats via non-inflammatory pathway

Kimuro Keiji, Yoshida Keimei, Izumi Ryo, Imabayashi Misaki, Masaki Kohei, Hosokawa Kazuya, Abe Kohtaro

Predictive Factors for Early Recovery from Mechanical Circulatory Support in Patients with Fulminant Myocarditis

Ueda Tomomi, Amiya Eisuke, Hatano Masaru, Ishida Junichi, Takeda Norifumi, Akazawa Hiroshi, Komuro Issei, Takeda Norihiko

You have to be authorized to contact abstract author. Please, Login
Not Available